Show simple item record

dc.contributor.authorPors, Klaus*
dc.contributor.authorGoldberg, F.W.*
dc.contributor.authorLeamon, C.P.*
dc.contributor.authorRigby, A.C.*
dc.contributor.authorSnyder, S.A.*
dc.contributor.authorFalconer, Robert A.*
dc.date.accessioned2016-08-17T14:34:07Z
dc.date.available2016-08-17T14:34:07Z
dc.date.issued2009-11
dc.identifier.citationPors K, Goldberg FW, Leamon CP, Rigby AC, Snyder SA, Falconer RA (2009) The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow. Drug Discovery Today, 14 (21/22): 1045-50.en_US
dc.identifier.urihttp://hdl.handle.net/10454/8821
dc.descriptionnoen_US
dc.description.abstractSince the development of the first cytotoxic agents, synthetic organic chemistry has advanced enormously. The synthetic and medicinal chemists of today are at the centre of drug development and are involved in most, if not all, processes of drug discovery. Recent decreases in government funding and reformed educational policies could, however, seriously impact on drug discovery initiatives worldwide. Not only could these changes result in fewer scientific breakthroughs, but they could also negatively affect the training of our next generation of medicinal chemists.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttp://www.sciencedirect.com/science/article/pii/S1359644609002323en_US
dc.subjectCancer drug discovery; Medicinal chemistry; Chemical biology; Diversity-oriented synthesis; EPSRC; Government funding; NCIen_US
dc.titleThe changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrowen_US
dc.status.refereedYesen_US
dc.typeArticleen_US
dc.type.versionpublished version paperen_US


This item appears in the following Collection(s)

Show simple item record